JW Asset Management LLC raised its position in shares of Antares Pharma, Inc. (NASDAQ:ATRS) by 27.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,671,956 shares of the specialty pharmaceutical company’s stock after buying an additional 362,431 shares during the period. Antares Pharma comprises about 3.4% of JW Asset Management LLC’s investment portfolio, making the stock its 6th largest position. JW Asset Management LLC owned about 1.07% of Antares Pharma worth $5,384,000 at the end of the most recent quarter.
Other large investors have also made changes to their positions in the company. Legal & General Group Plc acquired a new stake in shares of Antares Pharma during the second quarter worth about $120,000. Credit Suisse AG acquired a new stake in shares of Antares Pharma during the first quarter worth about $146,000. National Planning Corp boosted its stake in shares of Antares Pharma by 11.5% in the second quarter. National Planning Corp now owns 58,233 shares of the specialty pharmaceutical company’s stock worth $186,000 after buying an additional 6,000 shares during the last quarter. KCG Holdings Inc. boosted its stake in shares of Antares Pharma by 48.8% in the first quarter. KCG Holdings Inc. now owns 66,717 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 21,881 shares during the last quarter. Finally, Thompson Davis & CO. Inc. boosted its stake in shares of Antares Pharma by 80.8% in the first quarter. Thompson Davis & CO. Inc. now owns 68,386 shares of the specialty pharmaceutical company’s stock worth $194,000 after buying an additional 30,560 shares during the last quarter. 32.92% of the stock is owned by institutional investors.
Antares Pharma, Inc. (ATRS) opened at 3.06 on Monday. The company has a 50-day moving average price of $3.12 and a 200-day moving average price of $2.80. Antares Pharma, Inc. has a 1-year low of $1.08 and a 1-year high of $3.37. The firm’s market cap is $478.61 million.
Antares Pharma (NASDAQ:ATRS) last issued its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.01. Antares Pharma had a negative return on equity of 41.37% and a negative net margin of 34.27%. The business had revenue of $13.42 million during the quarter, compared to the consensus estimate of $12.99 million. On average, equities research analysts forecast that Antares Pharma, Inc. will post ($0.11) EPS for the current fiscal year.
WARNING: This report was published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://stocknewstimes.com/2017/08/21/jw-asset-management-llc-has-5-38-million-position-in-antares-pharma-inc-atrs.html.
A number of brokerages have recently issued reports on ATRS. HC Wainwright set a $5.00 target price on shares of Antares Pharma and gave the company a “buy” rating in a research report on Wednesday, August 9th. Vetr raised Antares Pharma from a “buy” rating to a “strong-buy” rating and set a $3.42 price target for the company in a research note on Monday, July 24th. Chardan Capital began coverage on Antares Pharma in a research note on Friday, June 23rd. They issued a “buy” rating and a $5.00 price target for the company. Finally, Piper Jaffray Companies set a $4.00 price target on Antares Pharma and gave the company a “buy” rating in a research note on Wednesday, July 26th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $4.34.
In related news, insider Fred M. Powell bought 130,000 shares of the business’s stock in a transaction on Friday, June 9th. The stock was acquired at an average price of $2.79 per share, for a total transaction of $362,700.00. Following the purchase, the insider now directly owns 331,434 shares in the company, valued at $924,700.86. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 11.60% of the stock is owned by company insiders.
About Antares Pharma
Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.
Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
